NYSE: HLNHaleon PLC Stock
$9.80-0.07 (-0.71%)
Updated Aug 3, 2026
HLN Price
$9.80
Fair Value Price
N/A
Market Cap
$43.87B
52 Week Low
$8.65
52 Week High
$11.28
P/E
N/A
P/B
2.01x
P/S
N/A
PEG
N/A
Dividend Yield
1.86%
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.99
Operating Cash Flow
N/A
Beta
0.26
Next Earnings
N/A
Ex-Dividend
Aug 14, 2026
Next Dividend
Sep 17, 2026
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HLN's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +17.17% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
C
HLN
Ranked#17 of 56
Ranked#17 of 56
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.00 | A | |
| $37.37 | A | |
| $18.85 | A |
Be the first to know about important HLN news, forecast changes, insider trades & much more!
HLN News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HLN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HLN is poor value based on its book value relative to its share price (2.01x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.58x)
P/B vs Industry Valuation
HLN's short-term liabilities ($8.33B) exceed its short-term assets ($5.72B)
Short-term Liabilities Financials
HLN's long-term liabilities ($13.20B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 35 more HLN due diligence checks available for Premium users.
Valuation
HLN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-2.87x
Market
14.82x
HLN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.01x
Industry
1.58x
HLN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HLN's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$43.4B
Liabilities
$21.5B
Debt to equity
0.99
HLN's short-term liabilities ($8.33B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HLN's long-term liabilities ($13.20B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
HLN vs Pharmaceutical Stocks
Haleon Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.